QTTB logo

Q32 Bio Inc.

QTTB
Healthcare|Biotechnology|US
$9.25
+0.40 (+4.52%)
DCF Value
$9.30
Tangible Book / Share
$12.55
Graham Number
$26.68
Cash / Share
$12.64
Next Earnings Report
Mar 9, 2027
EPS est. -$0.30 · Revenue est. $500.0K
Financing Filings (last 12 months)
8
Shelf registrations / offering prospectuses — latest Jul 28, 2026 (424B3). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Awaiting Results (2)

Trials past primary completion date but still active — data readout may be imminent.

Jun 2026
P2
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
NCT06018428
Dec 2024
P2
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
NCT05509023

Recent Press Releases

Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 4, 2026 · PRNewsWire
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
Sep 30, 2026 · PRNewsWire
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026
Sep 21, 2026 · PRNewsWire
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D.
Sep 14, 2026 · PRNewsWire
Q32 Bio to Participate in Upcoming September Investor Conferences
Sep 1, 2026 · PRNewsWire

SEC Filings (91)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 6, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 6, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 4, 202610-QQuarterly reportDocumentIndex
Nov 4, 20268-KMaterial eventDocumentIndex
Oct 28, 2026SC 13GPassive 5%+ stakeDocumentIndex
Oct 9, 2026SC 13GPassive 5%+ stakeDocumentIndex
Sep 30, 20268-KMaterial eventDocumentIndex
Sep 14, 20268-KMaterial eventDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 5, 202610-QQuarterly reportDocumentIndex
Aug 5, 20268-KMaterial eventDocumentIndex
Jul 31, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 28, 2026EFFECTDocumentIndex
Jul 28, 2026424B3Offering prospectusDocumentIndex
Jul 20, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Jul 17, 2026S-3Shelf registrationDocumentIndex
Jul 15, 20268-KMaterial eventDocumentIndex
Jul 15, 2026424B5Offering prospectusDocumentIndex
Jul 13, 2026EFFECTDocumentIndex
Jul 13, 2026424B5Offering prospectusDocumentIndex
Jul 13, 20268-KMaterial eventDocumentIndex
Jul 13, 20268-KMaterial eventDocumentIndex
Jul 10, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 6, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jun 25, 2026S-3Shelf registrationDocumentIndex
Jun 16, 20268-KMaterial eventDocumentIndex
Jun 4, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jun 4, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jun 1, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
May 28, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
May 27, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13GPassive 5%+ stakeDocumentIndex
May 6, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
May 6, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 5, 202610-QQuarterly reportDocumentIndex
May 5, 20268-KMaterial eventDocumentIndex
Apr 30, 2026ARSAnnual report to holdersDocumentIndex
Apr 30, 2026DEFA14AProxy / shareholder voteDocumentIndex